Brad Robling is the Vice President Corporate Business Development / Lilly New Ventures at Eli Lilly and Company. As such, he is focused on managing Eli Lilly’s venture capital investments globally. Prior to joining the Eli Lilly venture team, he held positions in business development and investor relations. Prior to joining Lilly, he held business development / finance positions in business development for a global 100 technology company and two startup companies in the Bay Area. He also spent over 10 years at financial / consulting companies: Deloitte Consulting and Ernst and Young.
Brad currently serves on the boards of Cedilla Therapeutics based in Boston, MA and Auron Therapeutics based in Wellesley, MA.